Call Us: US - +1 845 478 5244 | UK - +44 20 7193 7850 | AUS - +61 2 8005 4826

Understanding how the interplay between dietary fiber and gut microbiota

The Celis Laboratory studies the development of T cell-based immunotherapy for various cancer types. Efforts during 2015 were devoted towards the identification of novel T cell epitopes from tumor antigens and in the development of vaccines that induce anti-tumor T cell responses. In collaboration with investigators from Japan, Dr. Celis helped in the identification of CD4 T cell epitopes from HER-3 for head and neck cancers and described the combination of HER-3 targeted therapy and immunotherapy (Sci. Rep. 2015, 5:e1628). Also, in studies in collaboration with his Japanese collogues, Dr. Celis reported that chemokine signaling can be used as a novel target therapy against nasal natural killer/T cell lymphomas (Cancer Immunol Immunother. 2015, 64(6):697-705). In collaboration with scientists from the Moffitt Cancer Center (Tampa, FL), it was shown that targeting histone deacetylase 6 can increase immunity against melanomas (Mol Oncol. 2015, 9(7):1447-57). In collaboration with the Mayo Clinic, Dr. Celis showed that mutated BRAF oncogene emerges during tumor recurrences in a murine melanoma model after immunotherapy (Mol Ther. 2015, 23(5):845-56). Some studies on overcoming the negative effects of T regulatory cells using PTEN inhibitors were done in collaboration with Dr. D. Munn at the GRU Cancer Center (Sci Adv. 2015, 1(10):e1500845), which will help the optimization of cancer immunotherapy. In collaboration with investigators in Korea, the Celis Laboratory described an optimized peptide vaccine capable of inducing multiple CD8 T cell responses with strong anti-tumor effects (Oncoimmunol. 2015, 4 (11):e1043504). Lastly, Dr. Celis reported that the combination of STING activator c-di-GMP enhanced the potency of peptide vaccines against melanomas (Cancer Immunol Immunother. 2015, 64(8):1057- 66).